Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor Ximelagatran (H 376/95) Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)

Study identifier:SH-TPA-0005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor Ximelagatran (H 376/95) Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)

Medical condition

venous thromboembolism

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jul 2000
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria